Imported strongyloidiasis: Data from 1245 cases registered in the +REDIVI Spanish Collaborative Network (2009-2017).


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
05 2019
Historique:
received: 05 02 2019
accepted: 17 04 2019
revised: 29 05 2019
pubmed: 17 5 2019
medline: 28 10 2019
entrez: 17 5 2019
Statut: epublish

Résumé

Imported strongyloidiasis is increasingly being diagnosed in non-endemic areas. The aim of this study was to describe the epidemiological, clinical and microbiological characteristics of patients with imported strongyloidiasis in Spain. This is an observational retrospective study that included all patients diagnosed of strongyloidiasis registered in the +REDIVI Collaborative Network from 2009 to 2017. Demographic, epidemiological and clinical information was collected from the +REDIVI database, and extra information regarding microbiological techniques, treatment and follow-up was requested to participant centers. Overall, 1245 cases were included. Most of them were immigrants (66.9%), and South America was the most frequent area of origin. Detection of larvae in stool samples was observed in 21.9% of the patients, and serological tests allowed making the diagnosis in the rest of the cases. Eosinophilia was present in 82.2% of cases. Treatment with ivermectin (compared with albendazole) was the most strongly associated factor to achieve the cure (OR 2.34). Given the long latency of the infection and the risk of developing a severe presentation, screening of S. stercoralis infection should be mandatory in patients coming from or had traveling to endemic areas, especially in those with immunosuppressant conditions.

Sections du résumé

BACKGROUND
Imported strongyloidiasis is increasingly being diagnosed in non-endemic areas. The aim of this study was to describe the epidemiological, clinical and microbiological characteristics of patients with imported strongyloidiasis in Spain.
METHODOLOGY
This is an observational retrospective study that included all patients diagnosed of strongyloidiasis registered in the +REDIVI Collaborative Network from 2009 to 2017. Demographic, epidemiological and clinical information was collected from the +REDIVI database, and extra information regarding microbiological techniques, treatment and follow-up was requested to participant centers.
FINDINGS
Overall, 1245 cases were included. Most of them were immigrants (66.9%), and South America was the most frequent area of origin. Detection of larvae in stool samples was observed in 21.9% of the patients, and serological tests allowed making the diagnosis in the rest of the cases. Eosinophilia was present in 82.2% of cases. Treatment with ivermectin (compared with albendazole) was the most strongly associated factor to achieve the cure (OR 2.34).
CONCLUSIONS
Given the long latency of the infection and the risk of developing a severe presentation, screening of S. stercoralis infection should be mandatory in patients coming from or had traveling to endemic areas, especially in those with immunosuppressant conditions.

Identifiants

pubmed: 31095570
doi: 10.1371/journal.pntd.0007399
pii: PNTD-D-19-00166
pmc: PMC6541302
doi:

Substances chimiques

Anthelmintics 0
Ivermectin 70288-86-7
Albendazole F4216019LN

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0007399

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist

Références

Diagn Microbiol Infect Dis. 1994 Jan;18(1):19-23
pubmed: 8026153
Am J Trop Med Hyg. 1996 Nov;55(5):477-81
pubmed: 8940976
PLoS Negl Trop Dis. 2011 May 10;5(5):e1044
pubmed: 21572981
Clin Infect Dis. 2018 May 2;66(10):1558-1565
pubmed: 29360939
J Clin Microbiol. 2005 Apr;43(4):1932-3
pubmed: 15815023
Enferm Infecc Microbiol Clin. 2015 Jan;33(1):37-9
pubmed: 25205127
Southeast Asian J Trop Med Public Health. 2005 Mar;36(2):442-4
pubmed: 15916052
Clin Microbiol Rev. 2004 Jan;17(1):208-17
pubmed: 14726461
J Clin Microbiol. 2010 May;48(5):1716-9
pubmed: 20335415
PLoS Negl Trop Dis. 2013;7(1):e2002
pubmed: 23350004
Trans R Soc Trop Med Hyg. 2006 Nov;100(11):1056-62
pubmed: 16551471
Am J Trop Med Hyg. 2014 May;90(5):835-9
pubmed: 24615130
PLoS Negl Trop Dis. 2015 Feb 10;9(2):e0003491
pubmed: 25668740
PLoS Negl Trop Dis. 2014 Aug 14;8(8):e3018
pubmed: 25121962
Trans R Soc Trop Med Hyg. 2009 Oct;103(10):967-72
pubmed: 19328508
J Helminthol. 2017 Mar;91(2):262-266
pubmed: 27121364
PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2288
pubmed: 23875033
Indian J Med Microbiol. 2011 Apr-Jun;29(2):147-51
pubmed: 21654109
Int J Antimicrob Agents. 2008 Jan;31(1):46-9
pubmed: 18023151
Pathog Glob Health. 2014 Apr;108(3):137-40
pubmed: 24766337
Cochrane Database Syst Rev. 2016 Jan 18;(1):CD007745
pubmed: 26778150
Trop Med Int Health. 2017 Nov;22(11):1436-1441
pubmed: 28869694
BMC Infect Dis. 2013 Feb 08;13:78
pubmed: 23394259
Parasite Immunol. 2004 Nov-Dec;26(11-12):487-97
pubmed: 15771684
PLoS Negl Trop Dis. 2014 Jan 09;8(1):e2640
pubmed: 24427320
Am J Trop Med Hyg. 2017 Sep;97(3):645-652
pubmed: 28749768
Int J Surg. 2014 Dec;12(12):1500-24
pubmed: 25046751
Int J Infect Dis. 2014 Jan;18:32-7
pubmed: 24211226
J Helminthol. 2018 Jan;92(1):12-16
pubmed: 28112060
Euro Surveill. 2016 Aug 4;21(31):
pubmed: 27525375
J Parasitol. 1993 Apr;79(2):277-80
pubmed: 8459339
J Travel Med. 2017 Sep 1;24(5):
pubmed: 28931128
Am J Trop Med Hyg. 2014 May;90(5):830-4
pubmed: 24615124
Southeast Asian J Trop Med Public Health. 2000 Mar;31(1):147-51
pubmed: 11023084
Trans R Soc Trop Med Hyg. 1994 May-Jun;88(3):344-5
pubmed: 7974685

Auteurs

Fernando Salvador (F)

Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain.

Begoña Treviño (B)

Tropical Medicine and International Health Unit Drassanes-Vall d'Hebron, PROSICS Barcelona, Barcelona, Spain.

Sandra Chamorro-Tojeiro (S)

Ramón y Cajal University Hospital, Madrid, Spain.

Adrián Sánchez-Montalvá (A)

Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain.

Juan María Herrero-Martínez (JM)

Hospital Universitario 12 de Octubre, Madrid, Spain.

Azucena Rodríguez-Guardado (A)

Hospital Universitario Central de Asturias, Oviedo, Spain.

Núria Serre-Delcor (N)

Tropical Medicine and International Health Unit Drassanes-Vall d'Hebron, PROSICS Barcelona, Barcelona, Spain.

Diego Torrús (D)

Hospital General Universitario de Alicante, Alicante, Spain.

Josune Goikoetxea (J)

Hospital Universitario Cruces, Barakaldo, Spain.

Zuriñe Zubero (Z)

Hospital de Basurto, Bilbao, Spain.

María Velasco (M)

Hospital Universitario Fundación Alcorcón, Madrid, Spain.

Elena Sulleiro (E)

Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain.

Israel Molina (I)

Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain.

Rogelio López-Vélez (R)

Ramón y Cajal University Hospital, Madrid, Spain.

José Antonio Pérez-Molina (JA)

Ramón y Cajal University Hospital, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH